Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy

Congratulations are (still) in order for pharmaceutical giants Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY). Lilly's Zepbound and Mounjaro along with Novo's Saxenda and Wegovy remain the planet's best-selling weight-loss drugs, collectively generating over $40 billion in revenue last year alone.Let's face it, though. The drug industry isn't just going to let these two companies dominate this multibillion sliver of the business indefinitely. Rivals are going to take their shot. Some of them are even going to be successful with their entries into this race.An up-and-comer called BioAge Labs (NASDAQ: BIOA) is one of these would-be rivals. Although it's still very early stage for the mostly pre-revenue and pre-profit anti-obesity outfit -- and therefore still fairly risky for investors -- it's worth noting that analysts with Citigroup have turned firmly bullish on this ticker of late. Let's see why.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool